메뉴 건너뛰기




Volumn 58, Issue 9, 2013, Pages 2615-2622

Colonic 15-PGDH levels are stable across distance and time and are not perturbed by aspirin intervention

Author keywords

15 PGDH; Biomarker; Colon cancer; NSAIDs

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MESSENGER RNA;

EID: 84884207640     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2670-5     Document Type: Article
Times cited : (10)

References (22)
  • 1
    • 0036528298 scopus 로고    scopus 로고
    • Focus on colon cancer
    • 12086859 10.1016/S1535-6108(02)00053-3 1:CAS:528:DC%2BD38XjsFGltrk%3D
    • Markowitz SD, Dawson DM, Willis J, et al. Focus on colon cancer. Cancer Cell. 2002;1:233-236.
    • (2002) Cancer Cell , vol.1 , pp. 233-236
    • Markowitz, S.D.1    Dawson, D.M.2    Willis, J.3
  • 2
    • 0036407230 scopus 로고    scopus 로고
    • Genetic and epigenetic alterations in colon cancer
    • 12142355 10.1146/annurev.genom.3.022502.103043 1:CAS:528: DC%2BD3sXktlCktw%3D%3D
    • Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet. 2002;3:101-128.
    • (2002) Annu Rev Genomics Hum Genet , vol.3 , pp. 101-128
    • Grady, W.M.1    Markowitz, S.D.2
  • 3
    • 72449176846 scopus 로고    scopus 로고
    • Molecular origins of cancer: Molecular basis of colorectal cancer
    • 20018966 10.1056/NEJMra0804588 1:CAS:528:DC%2BD1MXhsFKisr7L
    • Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449-2460.
    • (2009) N Engl J Med , vol.361 , pp. 2449-2460
    • Markowitz, S.D.1    Bertagnolli, M.M.2
  • 4
    • 13544268334 scopus 로고    scopus 로고
    • 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer
    • 15542609 10.1074/jbc.M411221200 1:CAS:528:DC%2BD2MXovVCrug%3D%3D
    • Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005;280:3217-3223.
    • (2005) J Biol Chem , vol.280 , pp. 3217-3223
    • Backlund, M.G.1    Mann, J.R.2    Holla, V.R.3
  • 5
    • 33747081906 scopus 로고    scopus 로고
    • 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis
    • 16880406 10.1073/pnas.0603235103 1:CAS:528:DC%2BD28Xotlyju7Y%3D
    • Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA. 2006;103:12098-12102.
    • (2006) Proc Natl Acad Sci USA , vol.103 , pp. 12098-12102
    • Myung, S.J.1    Rerko, R.M.2    Yan, M.3
  • 6
    • 10644274362 scopus 로고    scopus 로고
    • 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers
    • 15574495 10.1073/pnas.0406142101 1:CAS:528:DC%2BD2MXhslOjtQ%3D%3D
    • Yan M, Rerko RM, Platzer P, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA. 2004;101:17468-17473.
    • (2004) Proc Natl Acad Sci USA , vol.101 , pp. 17468-17473
    • Yan, M.1    Rerko, R.M.2    Platzer, P.3
  • 7
    • 67249157211 scopus 로고    scopus 로고
    • 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors
    • 19470469 10.1073/pnas.0902367106 1:CAS:528:DC%2BD1MXot1CgurY%3D
    • Yan M, Myung SJ, Fink SP, et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci USA. 2009;106:9409-9413.
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 9409-9413
    • Yan, M.1    Myung, S.J.2    Fink, S.P.3
  • 8
    • 33748180713 scopus 로고    scopus 로고
    • Celecoxib for the prevention of colorectal adenomatous polyps
    • 16943401 10.1056/NEJMoa061652 1:CAS:528:DC%2BD28XovFehurc%3D
    • Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885-895.
    • (2006) N Engl J Med , vol.355 , pp. 885-895
    • Arber, N.1    Eagle, C.J.2    Spicak, J.3
  • 9
    • 0037421985 scopus 로고    scopus 로고
    • A randomized trial of aspirin to prevent colorectal adenomas
    • 12621133 10.1056/NEJMoa021735 1:CAS:528:DC%2BD3sXhvVOitrw%3D
    • Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.
    • (2003) N Engl J Med , vol.348 , pp. 891-899
    • Baron, J.A.1    Cole, B.F.2    Sandler, R.S.3
  • 10
    • 33748196958 scopus 로고    scopus 로고
    • Celecoxib for the prevention of sporadic colorectal adenomas
    • 16943400 10.1056/NEJMoa061355 1:CAS:528:DC%2BD28XovFaju7Y%3D
    • Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873-884.
    • (2006) N Engl J Med , vol.355 , pp. 873-884
    • Bertagnolli, M.M.1    Eagle, C.J.2    Zauber, A.G.3
  • 11
    • 0037421984 scopus 로고    scopus 로고
    • A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
    • 12621132 10.1056/NEJMoa021633 1:CAS:528:DC%2BD3sXhvVOisbw%3D
    • Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-890.
    • (2003) N Engl J Med , vol.348 , pp. 883-890
    • Sandler, R.S.1    Halabi, S.2    Baron, J.A.3
  • 12
    • 84860250352 scopus 로고    scopus 로고
    • Use of aspirin postdiagnosis improves survival for colon cancer patients
    • 22454078 10.1038/bjc.2012.101 1:CAS:528:DC%2BC38Xmt1Ghu7c%3D
    • Bastiaannet E, Sampieri K, Dekkers OM, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer. 2012;106:1564-1570.
    • (2012) Br J Cancer , vol.106 , pp. 1564-1570
    • Bastiaannet, E.1    Sampieri, K.2    Dekkers, O.M.3
  • 13
    • 83955161674 scopus 로고    scopus 로고
    • Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial
    • 22036019 10.1016/S0140-6736(11)61049-0
    • Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081-2087.
    • (2011) Lancet , vol.378 , pp. 2081-2087
    • Burn, J.1    Gerdes, A.M.2    Macrae, F.3
  • 14
    • 84855556537 scopus 로고    scopus 로고
    • Aspirin in the chemoprevention of colorectal neoplasia: An overview
    • 10.1158/1940-6207.CAPR-11-0391 1:CAS:528:DC%2BC38XjvValtb0%3D
    • Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5:164-178.
    • (2012) Cancer Prev Res (Phila) , vol.5 , pp. 164-178
    • Chan, A.T.1    Arber, N.2    Burn, J.3
  • 15
    • 64149097786 scopus 로고    scopus 로고
    • The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments
    • 19246619 10.1373/clinchem.2008.112797 1:CAS:528:DC%2BD1MXktVWqs7g%3D
    • Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611-622.
    • (2009) Clin Chem , vol.55 , pp. 611-622
    • Bustin, S.A.1    Benes, V.2    Garson, J.A.3
  • 16
    • 60549115231 scopus 로고    scopus 로고
    • Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1
    • 19188603 10.1073/pnas.0812904106
    • Chan CW, Wong NA, Liu Y, et al. Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1. Proc Natl Acad Sci USA. 2009;106:1936-1941.
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 1936-1941
    • Chan, C.W.1    Wong, N.A.2    Liu, Y.3
  • 17
    • 0025354008 scopus 로고
    • Identification of protein IT of the intestinal cytoskeleton as a novel type i cytokeratin with unusual properties and expression patterns
    • 1696264 10.1083/jcb.111.2.567 1:CAS:528:DyaK3cXkvFKqurk%3D
    • Moll R, Schiller DL, Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol. 1990;111:567-580.
    • (1990) J Cell Biol , vol.111 , pp. 567-580
    • Moll, R.1    Schiller, D.L.2    Franke, W.W.3
  • 18
    • 0032903863 scopus 로고    scopus 로고
    • Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months
    • 10334197 10.1093/carcin/20.5.805 1:CAS:528:DyaK1MXjtVantbw%3D
    • Williamson SL, Kartheuser A, Coaker J, et al. Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis. 1999;20:805-810.
    • (1999) Carcinogenesis , vol.20 , pp. 805-810
    • Williamson, S.L.1    Kartheuser, A.2    Coaker, J.3
  • 19
    • 34249711291 scopus 로고    scopus 로고
    • Aspirin and colon cancer-targeting prevention?
    • 17522404 10.1056/NEJMe078044 1:CAS:528:DC%2BD2sXlvVCntbc%3D
    • Markowitz SD. Aspirin and colon cancer-targeting prevention? N Engl J Med. 2007;356:2195-2198.
    • (2007) N Engl J Med , vol.356 , pp. 2195-2198
    • Markowitz, S.D.1
  • 20
    • 33845288081 scopus 로고    scopus 로고
    • A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas
    • 17087947 10.1053/j.gastro.2006.08.079 1:CAS:528:DC%2BD2sXhtFyltL8%3D
    • Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674-1682.
    • (2006) Gastroenterology , vol.131 , pp. 1674-1682
    • Baron, J.A.1    Sandler, R.S.2    Bresalier, R.S.3
  • 21
    • 19744380776 scopus 로고    scopus 로고
    • Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
    • 15713943 10.1056/NEJMoa050493 1:CAS:528:DC%2BD2MXit1Kqu7o%3D
    • Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
    • (2005) N Engl J Med , vol.352 , pp. 1092-1102
    • Bresalier, R.S.1    Sandler, R.S.2    Quan, H.3
  • 22
    • 20144365496 scopus 로고    scopus 로고
    • Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
    • 15713944 10.1056/NEJMoa050405 1:CAS:528:DC%2BD2MXit1Kqur4%3D
    • Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
    • (2005) N Engl J Med , vol.352 , pp. 1071-1080
    • Solomon, S.D.1    McMurray, J.J.2    Pfeffer, M.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.